Private Hospitals And Pharma Companies Stressed Over Government Affordable Medical Agenda

In order to provide affordable medical services in the country, the Government is going to take this decision in the new year with strong experience of Indian medicines and healthcare sector on the basis of tough decisions taken during the year 2017. The Government during the year instructed physicians to write only generic names of medicines, which prompted the pharmaceutical companies to worry deeply. Apart from this, the National Pharmaceutical Pricing Authority (NPPA) has determined the prices of medical instruments like stent and knee implants, which are used to treat cardiac arrest. Owing to this, the situation of those who manufacture them became uneasy.

Private Hospitals And Pharma Companies Stressed Over Government Affordable Medical Agenda

Max Hospital, Gurgaon remained in the discussion due to reasons such as charging higher prices and medical negligence. Both of these incidents question the treatment ways of private hospitals.

Regarding the year 2017, Indian Pharmaceutical Alliance, General Secretary, DG Shah stated that the pharma industry had never faced such challenges in the same year before. Providing generic medicines by physicians and giving a second drug at the place of medicine written by drug vendors has emerged as a major challenge for the industry.

Shah said that at the point of policy, increasing concern for export business, and drug regulatory reforms in the field of action, also became a matter of concern for the pharma industry in 2017.

Shah stressed, saying that the concerns will remain in 2018 as well. Proposals for amendment to the new drug policy without proper stakeholder consultation and non-evaluation assessment drugs price control order, 2013 will generate tribulations for the domestic industry in this complicated environment.

Similarly, on the other hand, the government is committed to providing affordable health care to the common man. In this order, the cost of precious medical devices stent and knee implantation system was reduced. The price of all types of stents has now come in the range of Rs 7,400 to 30,180 while the knee implant treatment has come down from Rs 54,720 to Rs 1, 13,950. These two steps of the government are expected to save the public’s Rs 5,950 Crore. The potential for savings of Rs 4,450 Crore and knee implantation on the stent front was estimated at Rs 1,500 Crore.

While on the other side, NPPA fixed the maximum prices of 255 medicines during January to November. The Government estimates that this step will save the consumers’ savings of Rs 2,643.37 Crore.